FDA Approves Teclistamab for Patients With Relapsed/Refractory MM

On October 25, 2022, the US Food and Drug Administration (FDA) granted expedited approval to teclistamab-cqyv for adult patients with relapsed or refractory multiple myeloma (MM) who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.